CYTOSORBENTS CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
CYTOSORBENTS CORPORATION (CTSO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.96 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-30
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.36.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $5.13, a 41.71% increase year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $3.62, a 20.96% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $4.58, a 1.08% decline year-over-year.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $0.96.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $2.59.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $5.73, a 28.48% increase from fiscal 2020.
- CYTOSORBENTS CORPORATION share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $4.46, a 9.05% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.96 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $0.96 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $2.59 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $2.61 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $2.65 10-Q · filed 2023-08-01 | ||||
| 2023-03-31 | $2.36 10-Q · filed 2023-05-02 | ||||
| 2021-12-31 | $5.73 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $5.78 10-Q · filed 2021-11-04 | ||||
| 2021-06-30 | $5.85 10-Q · filed 2021-08-03 | ||||
| 2021-03-31 | $5.13 10-Q · filed 2021-05-04 | ||||
| 2020-12-31 | $4.46 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $4.35 10-Q · filed 2020-11-04 | ||||
| 2020-06-30 | $4.27 10-Q · filed 2020-08-04 | ||||
| 2020-03-31 | $3.62 10-Q · filed 2020-05-05 | ||||
| 2019-12-31 | $4.09 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $4.10 10-Q · filed 2019-11-05 | ||||
| 2019-06-30 | $4.39 10-Q · filed 2019-08-06 | ||||
| 2019-03-31 | $4.58 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $3.65 10-K · filed 2021-03-09 | ||||
| 2018-09-30 | $3.78 10-Q · filed 2018-11-06 | ||||
| 2018-06-30 | $3.80 10-Q · filed 2018-08-02 | ||||
| 2018-03-31 | $4.63 10-Q · filed 2018-05-08 | ||||
| 2017-12-31 | $4.40 10-K · filed 2020-03-05 | ||||
| 2017-09-30 | $3.56 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $3.87 10-Q · filed 2017-08-07 | ||||
| 2017-03-31 | $4.45 10-Q · filed 2017-05-08 | ||||
| 2016-12-31 | $3.26 10-K · filed 2019-03-07 | ||||
| 2016-09-30 | $3.17 10-Q · filed 2016-11-07 | ||||
| 2016-06-30 | $1.88 10-Q · filed 2016-08-09 | ||||
| 2016-03-31 | $2.88 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $1.74 10-K · filed 2018-03-08 | ||||
| 2015-09-30 | $1.62 10-Q · filed 2015-11-13 | ||||
| 2015-06-30 | $2.22 10-Q · filed 2015-08-13 | ||||
| 2015-03-31 | $4.18 10-Q · filed 2015-05-11 | ||||
| 2014-12-31 | $0.97 10-K · filed 2017-03-03 | ||||
| 2014-09-30 | $0.04 10-Q · filed 2014-11-12 | ||||
| 2014-06-30 | $0.04 10-Q · filed 2014-08-12 | ||||
| 2014-03-31 | $0.04 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $1.00 10-K · filed 2015-03-31 | $0.04 10-K · filed 2014-03-31 | |||
| 2013-09-30 | $0.04 10-Q · filed 2013-11-06 | ||||
| 2013-06-30 | $0.04 10-Q · filed 2013-08-14 | ||||
| 2012-12-31 | $0.04 10-K · filed 2014-03-31 | ||||
| 2011-12-31 | $0.04 10-K · filed 2013-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |